What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities

Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test

(2015) Phil Skolnick et al.   ACTA NEUROPSYCHIATRICA

The promise of ketamine for treatment-resistant depression: current evidence and future directions

(2015) Kaitlin E. DeWilde et al.   Annals of the New York Academy of Sciences

Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics

(2015) Chadi G. Abdallah et al.   Annual Review of Medicine

Study of antidepressant drugs in GPR39 (zinc receptor−/−) knockout mice, showing no effect of conventional antidepressants, but effectiveness of NMDA antagonists

(2015) Katarzyna Młyniec et al.   BEHAVIOURAL BRAIN RESEARCH

Antidepressant actions of ketamine: from molecular mechanisms to clinical practice

(2015) Lisa M Monteggia et al.   CURRENT OPINION IN NEUROBIOLOGY

Inhibition of in vivo [3H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice

(2015) Alda Fernandes et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Faster, better, stronger: Towards new antidepressant therapeutic strategies

(2015) Olivia F. O’Leary et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Annual Research Review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents

(2015) Guilherme V. Polanczyk et al.   JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY

Immunomodulatory activity of ketamine in human astroglial A172 cells: Possible relevance to its rapid antidepressant activity

(2015) Yael Yuhas et al.   JOURNAL OF NEUROIMMUNOLOGY

Randomized Proof of Concept Trial of GLYX-13, an N-Methyl-D-Aspartate Receptor Glycine Site Partial Agonist, in Major Depressive Disorder Nonresponsive to a Previous Antidepressant Agent

(2015) SHELDON PRESKORN et al.   Journal of Psychiatric Practice

The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus

(2015) J. Burgdorf et al.   NEUROSCIENCE

Ketamine and other potential glutamate antidepressants

(2015) Arpan Dutta et al.   PSYCHIATRY RESEARCH

On the significance of elektroconvulsive therapy in the treatment of severe mental diseases

(2015) Michael Grözinger et al.   WIENER KLINISCHE WOCHENSCHRIFT

Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test

(2015) Phil Skolnick et al.   ACTA NEUROPSYCHIATRICA

Targeting of NMDA Receptors in the Treatment of Major Depression

(2014) Yong-Hui Dang et al.   CURRENT PHARMACEUTICAL DESIGN

Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression

(2014) E. Drewniany et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?

(2014) Gerard Sanacora et al.   NEUROPSYCHOPHARMACOLOGY

Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan

(2014) Linda Nguyen et al.   PLoS One

Short-term escitalopram treatment and hippocampal volume

(2014) Beata R. Godlewska et al.   PSYCHOPHARMACOLOGY

Nicotinic α7 receptor activation selectively potentiates the function of NMDA receptors in glutamatergic terminals of the nucleus accumbens

(2014) Stefania Zappettini et al.   Frontiers in Cellular Neuroscience

GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine

(2014) Oliver H Miller et al.   eLife

Synaptic Mechanisms Underlying Rapid Antidepressant Action of Ketamine

(2013) Ege T. Kavalali et al.   AMERICAN JOURNAL OF PSYCHIATRY

Pharmacological Properties of Glutamatergic Drugs Targeting NMDA Receptors and their Application in Major Depression

(2013) Gianluca Serafini et al.   CURRENT PHARMACEUTICAL DESIGN

Antidepressant Augmentation Using theN-Methyl-d-Aspartate Antagonist Memantine

(2013) Eric G. Smith et al.   JOURNAL OF CLINICAL PSYCHIATRY

Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects

(2013) G Sanacora et al.   MOLECULAR PSYCHIATRY

Conceptual Confluence: The Kynurenine Pathway as a Common Target for Ketamine and the Convergence of the Inflammation and Glutamate Hypotheses of Depression

(2013) Andrew H Miller   NEUROPSYCHOPHARMACOLOGY

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders

(2013) Michael Bauer et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

(2013) Caroline A. Browne et al.   Frontiers in Pharmacology

Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial

(2012) Carlos A. Zarate et al.   BIOLOGICAL PSYCHIATRY

A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression

(2012) Carlos A. Zarate et al.   BIOLOGICAL PSYCHIATRY

Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study

(2012) Lobna Ibrahim et al.   NEUROPSYCHOPHARMACOLOGY

Effects of Venlafaxine and Escitalopram Treatments on NMDA Receptors in the Rat Depression Model

(2011) Nigar Yilmaz et al.   JOURNAL OF MEMBRANE BIOLOGY

Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatergic neurotransmission?

(2011) Johann Steiner et al.   Journal of Neuroinflammation

Dextromethorphan as a potential rapid-acting antidepressant

(2011) Edward C. Lauterbach   MEDICAL HYPOTHESES

Signaling pathways underlying the rapid antidepressant actions of ketamine

(2011) Ronald S. Duman et al.   NEUROPHARMACOLOGY

The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder

(2011) Courtney S. Jernigan et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex

(2010) E. Ampuero et al.   NEUROSCIENCE

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

(2010) N. Li et al.   SCIENCE

Overview of the Genetics of Major Depressive Disorder

(2010) Falk W. Lohoff   Current Psychiatry Reports

How much cognitive therapy, for which patients, will prevent depressive relapse?

(2008) Robin B. Jarrett et al.   JOURNAL OF AFFECTIVE DISORDERS

An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

(2008) Sheldon H. Preskorn et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy

(2008) M. Taylor et al.   JOURNAL OF PSYCHOPHARMACOLOGY